Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pfs25M-EPA/AS01 and Pfs230D1M-EPA/AS01 TBV in Malian Adults
NCT02942277Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Oct 2016
- Primary completion
- Jul 2020
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pfs25m-epa and Pfs230D1-EPA in malaria (11 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Number of Participants With Local and Systemic Adverse Events at Year 2. Started Oct 2016; status: completed.
02
Drugs
pfs25m-epaPfs230D1-EPA
03
Conditions
malaria
Beyond the preview
Go deeper on NCT02942277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02942277.